Conor Medsystems remedies Nasdaq non-compliance

By Lisa Kerner

Erie, Pa., Feb. 15 - Conor Medsystems, Inc. said it has remedied a previous non-compliance with the Nasdaq Listing Qualifications Department. The company had been in non-compliance with the audit committee composition requirements for three days as the result of the resignation of George Milne from the board of directors on Feb. 6.

Conor remedied the non-compliance with the appointment of Steven Gerber to the audit committee on Feb. 10.

Nasdaq indicated by letter that Conor is now in compliance with Marketplace Rule 4350(d).

Conor develops innovative controlled vascular drug delivery technologies and is located in Menlo Park, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.